[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-343358-105":59,"doc-detail-343358-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","proteogenomic-characterization-identifies-clinical-subgroups-in-egfr-and-alk-wild-type-never-smoker-lung-adenocarcinoma","Proteogenomic characterization identifies clinical subgroups in EGFR and ALK wild-type never-smoker lung adenocarcinoma","","Never-smoker lung adenocarcinoma patients lacking key oncogenic drivers such as EGFR and ALK mutations have limited targeted-therapy options and often show worse outcomes with immune checkpoint inhibitors than smokers. To address the unmet need for precise molecular classification, this study integrates genome, transcriptome, and LC-MS/MSTMT proteome data from 99 Korean never-smoker patients. EGFR/ALK-wild-type NSLA tumors were divided into four proteogenomic subgroups—proliferation, angiogenesis, immune, and metabolism—each linked to distinct clinical outcomes. Genomic correlates with expression and proteome highlighted ERBB, neurotrophin, insulin, and MAPK signaling, and suggested targetable genes and proteins for therapy and combination immunotherapy.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/proteogenomic-characterization-identifies-clinical-subgroups-in-egfr-and-alk-wild-type-never-smoker-lung-adenocarcinoma/343358/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/proteogenomic-characterization-identifies-clinical-subgroups-in-egfr-and-alk-wild-type-never-smoker-lung-adenocarcinoma/343358.png","ImageObject",300,407,{"name":92,"@type":93},"Rowan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-26","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Which patient cohort and tumor type does the study focus on?","Question",{"text":112,"@type":113},"The study analyzes tumors from 99 Korean never-smoker lung adenocarcinoma patients, specifically NSLA tumors that are EGFR- and ALK-wild-type and lack key driver mutations.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How many proteogenomic subgroups are identified, and what are they?",{"text":117,"@type":113},"NSLA tumors without EGFR or ALK driver oncogenes are classified into four proteogenomic subgroups: proliferation, angiogenesis, immune, and metabolism.",{"name":119,"@type":110,"acceptedAnswer":120},"What is the main relationship between the subgroups and clinical outcomes?",{"text":121,"@type":113},"The four molecular subgroups are strongly associated with distinct clinical outcomes: proliferation and angiogenesis correspond to poorer prognosis, while the immune subtype shows the most favorable outcome, validated in an external dataset.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},343358,1790193033,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099514067415,"https://ap-avatar.wpscdn.com/avatar/100002539d78ffe74a7?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779092875211072502","[www.nature.com/emm](www.nature.com/emm)  \nARTICLE OPEN  \nProteogenomic characterization identiﬁes clinical subgroups in EGFR and ALK wild-type never-smoker lung adenocarcinoma  \nHyondeog Kim 1,12, Wonyeop Lee2,12, Youngwook Kim1,3,12 ✉, Sang-Jin Lee4, Wonyoung Choi 5, Geon Kook Lee6, Seung-Jin Park7,8, Shinyeong Ju9, Seon-Young Kim7,8,10, Cheolju Lee 9,11 and Ji-Youn Han2 ✉  \n© The Author(s) 2024  \n\n|  | Patients with lung adenocarcinoma who have never smoked (NSLA) and lack key driver mutations, such as those in the EGFR and ALK genes, face limited options for targeted therapies. They also tend to have poorer outcomes with immune checkpoint inhibitors than lung cancer patients who have a history of smoking. The proteogenomic proﬁle of nonsmoking lung adenocarcinoma patients without these oncogenic driver mutations is poorly understood, which complicates the precise molecular classiﬁcation of these cancers and highlights a signiﬁcant area of unmet clinical need. This study analyzed the genome, transcriptome, and LC‒MS/MSTMT-driven proteome data of tumors obtained from 99 Korean never-smoker lung adenocarcinoma patients. NSLA tumors without EGFR or ALK driver oncogenes were classiﬁed into four proteogenomic subgroups: proliferation, angiogenesis, immune, and metabolism subgroups. These 4 molecular subgroups were strongly associated with distinct clinical outcomes. The proliferation and angiogenesis subtypes were associated with a poorer prognosis, while the immune subtype was associated with the most favorable outcome, which was validated in an external lung cancer dataset. Genomic-wide impacts were analyzed, and signiﬁcant correlations were found between copy number alterations and both the transcriptome and proteome for several genes, with enrichment in the ERBB, neurotrophin, insulin, and MAPK signaling pathways. Proteogenomic analyses suggested several targetable genes and proteins, including CDKs and ATR, as potential therapeutic targets in the proliferation subgroup. Upregulated cytokines, such as CCL5 and CXCL13, in the immune subgroup may serve as potential targets for combination immunotherapy. Our comprehensive |  |\n| --- | --- | --- |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| proteogenomic analysis revealed the molecular subtypes of EGFR- and ALK-wild-type NSLA with signiﬁcant unmet clinical needs. |  |  |\n|  | Experimental & Molecular Medicine (2024) 56:2082–2095; [https://doi.org/10.1038/s12276-024-01320-0](https://doi.org/10.1038/s12276-024-01320-0) |  |\n|  |  |  |\n\nINTRODUCTION  \nLung cancer is the leading cause of cancer death, with an annual incidence of approximately 2 million cases worldwide1. While smoking remains the primary cause of lung cancer, never-smoker lung cancer is an increasingly concerning public health issue, particularly in Asian female populations, with its incidence steadily rising worldwide over the last several decades2. Most of these cancers exhibit a biologically simple cancer network, often characterized by a single predominant oncogenic driver, such asan EGFR or ALK mutation. Blockade of these mutations by tyrosine kinase inhibitors (TKIs) typically results in an initial clinical response lasting several months2–4. However, a considerable proportion of never-smokers with lung cancer lack these identiﬁable major driver mutations, which poses a challenge for the application of targeted therapies.  \nRecent clinical trials have reported markedly improved survival in lung cancer patients receiving immune checkpoint inhibitors  \n(ICIs) either as monotherapy or in combination with cytotoxic chemotherapy5–7. While ICIs generally improve clinical outcomesin current- and former-smokers with lung cancer, never-smokers typically exhibit a lower tumor mutation burden (TMB) and a reduced presence of immune components, leading to limited clinical beneﬁt from ICIs8. Never-smoker non-small cell lung c","cbCairJIW57zytLw","https://ap.wps.com/l/cbCairJIW57zytLw","pdf",6489295,14,"English","# Introduction\n# Proteogenomic classification and clinical outcomes\n# Genomic, transcriptomic, and proteomic correlations\n# Pathway enrichment and targetable candidates\n# Therapeutic implications","[{\"question\":\"Which patient cohort and tumor type does the study focus on?\",\"answer\":\"The study analyzes tumors from 99 Korean never-smoker lung adenocarcinoma patients, specifically NSLA tumors that are EGFR- and ALK-wild-type and lack key driver mutations.\"},{\"question\":\"How many proteogenomic subgroups are identified, and what are they?\",\"answer\":\"NSLA tumors without EGFR or ALK driver oncogenes are classified into four proteogenomic subgroups: proliferation, angiogenesis, immune, and metabolism.\"},{\"question\":\"What is the main relationship between the subgroups and clinical outcomes?\",\"answer\":\"The four molecular subgroups are strongly associated with distinct clinical outcomes: proliferation and angiogenesis correspond to poorer prognosis, while the immune subtype shows the most favorable outcome, validated in an external dataset.\"}]","Proteogenomic characterization identifies clinical subgroups in EGFR and ALK wild-type never-smoker lung adenocarcinoma | PDF",1790050883,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/83106ba6ea71a8bce8a34d457f8eaf9c.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0711b0335e473a40fd64c6ac21be0e3a.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5891b4b3235f6f4a44be6efb9c66c449.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/07db9a1aff276bbe213a7395277e6b48.webp",980,1301]